Jump to Header Jump to Main Content Jump to Footer

Ph II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas w/ SMO/ AKT/ NF2 Mutations

Daniela Bota


A Study On:

  • Brain and Nervous System

Status:

  • Open

Eligibility

Adults

Interested in joining this trial?

Official Title

Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 /CDK Pathway Mutations

Details

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Eligibility

You can join if...

Inclusion Criteria:

  • Histologically proven intracranial meningioma as documented by
    central pathology review
  • Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, PTEN
    mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1
    copy number gain in tumor sample as documented specifically by the central laboratory
  • Male or female who are not pregnant and not nursing

Exclusion Criteria:

  • Patients who have active bacterial infection
  • Patients who have history of heart diseases as described by the study protocol
  • Patients who have uncontrolled hypertension

Get in touch with our study team